High-dose chemotherap. and autologous blood stem-cell transplantation (ASCT) followed by lenalidomide maintenance (LenMT) is the current standard of care for patients with multiple myeloma (MM). However, dose reductions of LenMT are often necessary. Fenk and colleagues performed a clinical trial of MM patients after ASCT and high-dose lenalidomide consolidation therapy (CT) at 25 mg/day were randomized to receive LenMT at either 25 or 5 mg/day. Patients receiving high dose LenMT showed improved PFS compared with patients receiving low dose. Adverse events were more common in patients in the high-dose arm but decreased after dose-adjustments. Therefore, the maximum tolerated dose of LenMT varied among patients and needs to be individually tailored. Long-term follow-up studies may further refine the dosing implications of LenMT.

CDK4/6 inhibitors plus endocrine therapy improves overall survival in women with estrogen receptor (ER)-positive HER2-negative advanced breast cancer. However, this combination has not been studied in HER2+ disease. Ciruelos...

You do not currently have access to this content.